Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.42 |
| ▸ | CDK2 | P24941 | 11/20 | 0.42 |
| ▸ | GSK3B | P49841 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436676 | 1.00 | TYR (0.54) | TYREPHX1CCNE1CDK2GSK3B | |
| SCHEMBL7246057 | 0.86 | TYR (0.56) | TYREPHX1BCHE | |
| SCHEMBL5620106 | 0.83 | TYR (0.53) | TYRCCNE1CDK2GSK3B | |
| SCHEMBL5620104 | 0.83 | TYR (0.53) | TYRCCNE1CDK2GSK3B | |
| SCHEMBL5619056 | 0.83 | TYR (0.52) | TYRCA12CA1CA2CA7 | |
| SCHEMBL5620809 | 0.83 | TYR (0.64) | TYRBCHE | |
| SCHEMBL5620805 | 0.83 | TYR (0.64) | TYRBCHE | |
| SCHEMBL5618879 | 0.82 | TYR (0.59) | TYRCA12CA1CA2CA7 | |
| SCHEMBL5618872 | 0.82 | TYR (0.59) | TYRCA12CA1CA2CA7 | |
| SCHEMBL6435344 | 0.81 | EPHX1 (0.54) | TYREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | claimed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | claimed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | claimed |
| US-6933319-B2 | Resorcinol derivatives | PFIZER INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050143594-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART E (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1165495-B1 | RESORCINOL DERIVATIVES | PFIZER (US) | 2005-04-20 | — | — | EP | disclosed |
| US-6861564-B2 | Process for preparing resorcinol derivatives | PFIZER INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-6828460-B2 | Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors | PFIZER INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040209949-A1 | Resorcinol derivatives | BROWNING ANDREW FRANCIS (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | BRADLEY STUART EDWARD (GB) | 2003-05-08 | — | — | US | disclosed |
| US-6504037-B2 | Reacting a cyclohexanedione or chromene-one derivative with 1,8-diazabicyclo(5.4.0)undec-7ene | WARNER-LAMBERT COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020161041-A1 | Resorcinol derivatives | PFIZER INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | PFIZER PRODUCTS INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1165495-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1134207-A1 | Process for preparing resorcinol derivatives | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000056702-A1 | RESORCINOL DERIVATIVES | PFIZER INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143594-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | TYR 572/4885EPHX1 827/4885CCNE1 2222/4885 |
| US-20030088113-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | TYR 572/4885EPHX1 827/4885CCNE1 2222/4885 |
| US-20040209949-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | TYR 9/4885EPHX1 1049/4885CCNE1 3483/4885 |
| US-20020032352-A1 | Process for preparing resorcinol derivatives | CYP4B1, CYP4A11, POR | TYR 572/4885EPHX1 827/4885CCNE1 2222/4885 |
| US-20020161041-A1 | Resorcinol derivatives | NQO1, LRAT, ALDH1A2 | TYR 9/4885EPHX1 1049/4885CCNE1 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.